BERKELEY'S NEWS • OCTOBER 01, 2022

Advancements in CRISPR technology discovered amid ongoing patent dispute

article image

SUPPORT OUR NONPROFIT NEWSROOM

We're an independent student-run newspaper, and need your support to maintain our coverage.

JANUARY 18, 2017

Researchers at UC Berkley and UCSF published new findings about gene-modifying proteins in December connected to their research of CRISPR technology, a natural bacterial defense mechanism that is the subject of an ongoing patent dispute.

In a publication released Dec. 22, principal investigator Jennifer Doudna of UC Berkeley and other researchers summarized their discovery of the previously unknown CRISPR and the presence of the Cas9 protein in nanoarchaeum, which are smaller versions of single-celled microorganisms.

Researchers at UCSF’s Bondy-Denomy Lab, which studies the way bacteria fight off viruses known as bacteriophages within microbial ecosystems, published a paper Dec. 29 about their discovery of “anti-CRISPR proteins,” bacteriophages that stop Cas9 proteins from binding to DNA.

“The basic framework (of) CRISPR is that it exists in bacteria and archaea to protect from viruses,” said Joseph Bondy-Denomy, principal investigator at the Bondy-Denomy Lab.

The Doudna Lab at UC Berkeley, which specializes in RNA biology, conducts CRISPR research. Doudna has co-authored several scientific papers documenting her team’s applications of the CRISPR-Cas9 gene-editing system.

The Cas9 protein is also the subject of the patent debate between UC Berkeley and the Broad Institute of the Massachusetts Institute of Technology and Harvard University, in which both teams claim that they were first to discover the protein’s usefulness in gene manipulation and regulation. The two groups are undergoing a legal process called a patent interference, in which the U.S. Patent and Trademark Office will determine whether an overlap exists between each method of using the technology.

According to Bondy-Denomy, Cas9 is still widely shared and utilized among researchers amid the ongoing patent debate.

“Our focus is studying the natural biology of these proteins,” Bondy-Denomy said. ”We’re not done surveying all that nature can give us in CRISPR. It still deserves a lot of attention.”

Contact Justin Sidhu at 

LAST UPDATED

JANUARY 18, 2017


Related Articles

featured article
The Patent Trial and Appeal Board heard arguments regarding a patent dispute over the methods employed in CRISPR, a natural bacterial defense mechanism that some scientists have used to modify DNA.
The Patent Trial and Appeal Board heard arguments regarding a patent dispute over the methods employed in CRISPR, a natural bacterial defense mechanism that some scientists have used to modify DNA.
featured article
featured article
The U.S. Patent and Trademark Office issued Caribou Biosciences, a startup co-founded by UC Berkeley researcher Jennifer Doudna, intellectual property rights for developments in CRISPR gene-editing technology Tuesday.
The U.S. Patent and Trademark Office issued Caribou Biosciences, a startup co-founded by UC Berkeley researcher Jennifer Doudna, intellectual property rights for developments in CRISPR gene-editing technology Tuesday.
featured article
featured article
The U.S. Patent and Trademark Office agreed Monday to decide whether a UC Berkeley research team will be awarded the rights to the groundbreaking CRISPR-Cas9 technology, which could be worth billions of dollars and serve as the foundation for the burgeoning field of gene editing.
The U.S. Patent and Trademark Office agreed Monday to decide whether a UC Berkeley research team will be awarded the rights to the groundbreaking CRISPR-Cas9 technology, which could be worth billions of dollars and serve as the foundation for the burgeoning field of gene editing.
featured article